Quelles chances pour la France dans un monde globalisé? – Jeudi 26 février de 18h à 20h

 

François Nicoullaud, President ADFE-Français du Monde

Les Français, qui n’ont pas renoncé à jouer un rôle à l’échelle mondiale, s’inquiètent plus que jamais de la compétition entre nations et entre continents nourrie par le phénomène de mondialisation, et encore exacerbée par la crise…. Peut-on parler d’un déclin, au moins relatif, dans lequel notre pays serait engagé? Ou au contraire de quels atouts disposons-nous pour continuer à exister et à faire exister nos valeurs dans le monde de demain?

Jeudi 26 février de 18h à 20h à l’Ecole Internationale de Boston à Cambridge (45 Matignon Road – Cambridge). Pour plus d’informations, vous pouvez accéder au plan d’accès en cliquant ici. La salle est la Salle d’honneursituée dans le bâtiment principal au 1er étage.

Extensive coverage

“One other thing I’ve done, is I’ve called on private sector mortgage banks and banks to be more aggressive about lending money to first-time home buyers. And the response has been really good. There’s a lot of people in this — our communities around the country that deeply care about the issue of homeownership, and they’ve been responsive.”

- George W. Bush, U.S. President, March 26, 2004. from Barry Ritholtz/The Big Picture

“Behind the crisis of subprime mortgages, there has been the crisis of subprime incomes.” Harold Meyerson/Washington Post

“The message is simple. Raising capital will be much more difficult now.” Ron Conway/Tech Crunch

Biocitech : les entreprises du site ont déposé plus de 30 demandes de brevets en 2007

Grâce à ce chiffre, Biocitech se place au troisième
rang national des déposants dans le domaine des sciences de la
vie. L’ « effet campus » a aussi suscité plus
d’une trentaine de partenariats entre les entreprises de
Biocitech

Biocitech, le 21 avril 2008 – Biocitech, le parc
technologique parisien dédié aux sciences de la vie, annonce aujourd’hui que les
entreprises qu’il héberge ont déposé plus de 30 demandes de brevets au cours de
l’année 2007. Ce chiffre positionne Biocitech en troisième position pour le
nombre de dépôts dans le domaine des sciences de la vie, derrière le CNRS et
sanofi-aventis, et parmi les 50 premiers déposants nationaux, selon le nombre de
brevets publiés pour l’an dernier. Il s’agit d’une illustration forte des
recherches et avancées scientifiques rendues possibles par l’effet de synergie
engendré entre les entreprises présentes sur le campus.

www.biocitech.com

House Republicans Move To Increase H1B Visa Quota

Last Friday the House Republican Study Committee sent a letter to Nancy
Pelosi and Steny Hoyer, the Speaker of the House and Majority Leader,
respectively, requesting an increase in the current H1B visa quota of 65,000 per year to 115,000.
More

Top 10 Up-And-Coming Tech Cities

William Pentland, Forbes – 03.10.08

[...] The cities on this list aren’t the places you’d expect to be up-and-coming centers for the next generation of technologies,” said Auerswald, “But 30 years ago, few would have imagined Las Vegas as the center of a real estate boom.”

Auerswald surveyed specific pockets of science–including advanced materials, nano-crystals and quantum dots, polymers and plastics, micro-systems and cell microbiology–that most experts consider today’s most promising frontiers of innovation.

Borrowing a method devised by Anthony Breitzman, a researcher at 1790 Analytics, an intellectual-property valuation firm, Auerswald then looked for important relationships among patents within each general technical area. The most important patents are generally referenced by other inventors in the field when they file for their own patents; lesser patents garner fewer citations. The greater the increase in the number of important patents in a given city, the higher it ranked on Auerswald’s list. [...] more

Better finance for more enterprise growth in Europe

The corporate giants of Europe are aging elders. This column suggests financial reforms to encourage the growth of emerging
enterprises.

The recent financial turmoil will certainly lead policy-makers to reconsider existing regulations of financial markets and institutions. It would be misguided to focus exclusively on stability, however. What the European financial system lacks above all is the ability to foster the growth of emerging companies. According to Aghion, Fally and Scarpetta (2007), among others, financial development is particularly important for the entry and expansion of new businesses, possibly more so than labour market flexibility. We take this logic one step further and argue that some types of financial developments are more needed than others at this stage in the economic history of Europe.

The lack of emerging firms in Europe

Entry, exit, and the reallocation of resources among firms play a crucial role in the process of economic growth.¹Europe’s corporate landscape, however, is dominated by old, established companies. A look at the age distribution of the world’s 500 largest listed companies shows that European ‘champions’ are generally much older than American ones, let alone those from emerging markets, as illustrated by Figure 1. Europe’s corporate giants include only 12 companies born in the second half of the 20th century, against 51 in the US and 46 in emerging countries.

More from VoxEU

Boston-NY commutes: bus & train make more sense

“In Boston, Michael Brennan, property manager for the private company
that operates the South Station bus terminal, said total passenger
traffic has risen about 2,000 people a day in recent years to 12,000 on
average, driven by lower fares and the ease of use compared to flying.
Business travelers and students alike take advantage of the low fares.”

“Buses aren’t alone in seeing traffic spikes to New York. Amtrak reports
it carried 613,000 people between its three Boston-area stops last year
and New York’s Penn Station, up from 460,800 in 2006. At the same time,
air travel seems to be under pressure: Farecompare.com
shows 624,679 passengers flying from Boston’s Logan airport to New
York’s LaGuardia airport for the first 11 months of 2007, the latest
data available. That’s about 10,000 fewer people than in the same
period in 2006. Rick Seaney, the firm’s chief executive, said the
difference likely reflects fewer seats on the route and rising costs
pressuring people to take the train or bus.”

More from Boston Globe

Miracle of Science – Cambridge, Central Square

321 Massachusetts Ave
Cambridge, MA 02139
(617) 868-2866

First thing first. Miracle is still one of my favourites for an afterwork beer that can lead to another one before dinner. Also a nice place for a burger… with a beer. Nice music, cheerful atmosphere. As a coincidence I used to spent most of my stays in Cambridge at Hotel@MIT (Now Le Meridien), accross the street. I’m a few blocks away now, but still a good neighbor.

Do you know Céline Héchard?

· What is it you do?
I m in charge of I-STEM partnerships and business development. I-STEM (Institute for Stem Cells in the Treatment and Study of Monogenic Diseases) is involve in the evaluation of the full therapeutic potential of all types of human stem cells in the treatment of monogenic diseases. · What is your next exciting milestone?
The next exciting partnership for I-STEM scientists.

· Where will you spend you next holiday and why?
Morgins, Switzerland (http://www.morgins.ch) where my sister lives. We plan to have some ski and fun.

· Favorite bar in Paris? Another city (anywhere in the world)?
Restaurants : Le Balzac, Paris or Spoon, Paris

Do you know Jeff Behrens?

What is it you do?
I source exciting science from academic institutions and start companies to develop these ideas into important therapeutics.
What is your next exciting milestone?
Start our next company.
Where will you spend you next holiday and why?
Cancun, Mexico – escaping Boston’s cold weather and enjoying the sun and the beach with my family.
Favorite bar in Boston? Another city (anywhere in the world)?
The Biltmore (Newton, MA) – a terrific gastropub. Buddakan’s bar in New York city is excellent too…
Jeff is the Head of Business Operations, BI3 , the New Ventures Incubator of  Biogen Idec.